Thurston Springer Miller Herd & Titak Inc. Raises Stock Position in AbbVie Inc. $ABBV

Thurston Springer Miller Herd & Titak Inc. raised its position in AbbVie Inc. (NYSE:ABBV) by 76.1% in the 2nd quarter, Holdings Channel reports. The firm owned 7,148 shares of the company’s stock after buying an additional 3,090 shares during the quarter. AbbVie accounts for 0.7% of Thurston Springer Miller Herd & Titak Inc.’s holdings, making the stock its 29th largest position. Thurston Springer Miller Herd & Titak Inc.’s holdings in AbbVie were worth $1,799,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Willner & Heller LLC grew its position in AbbVie by 0.7% during the second quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after buying an additional 43 shares in the last quarter. Bank of Jackson Hole Trust increased its holdings in AbbVie by 0.6% in the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after buying an additional 44 shares during the period. Eclectic Associates Inc. ADV raised its stake in shares of AbbVie by 0.8% in the 4th quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock valued at $1,337,000 after buying an additional 45 shares in the last quarter. Imprint Wealth LLC raised its stake in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares in the last quarter. Finally, Dogwood Wealth Management LLC lifted its holdings in shares of AbbVie by 10.8% during the 4th quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock worth $108,000 after acquiring an additional 46 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

ABBV stock opened at $245.82 on Friday. The company has a 50 day moving average price of $241.96 and a 200 day moving average price of $224.96. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The stock has a market capitalization of $434.31 billion, a PE ratio of 69.44, a price-to-earnings-growth ratio of 0.81 and a beta of 0.30.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same period last year, the firm earned $2.97 EPS. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts expect that AbbVie Inc. will post 14.06 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. AbbVie’s payout ratio is presently 195.48%.

Analysts Set New Price Targets

ABBV has been the topic of a number of analyst reports. Citigroup upped their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday. Bank of America upped their price objective on AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a research note on Friday, July 10th. UBS Group raised their target price on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Monday, July 13th. Finally, BMO Capital Markets boosted their price target on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $275.70.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.